A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of [Rifampin] on the Pharmacokinetics of a Single Oral Dose of [GW679769]

This study will examine what the body does while taking GW679769 alone and together with rifampin in healthy adult subjects.

Inclusion criteria:

• healthy
• female subjects who cannot become pregnant
• able to swallow and keep down oral medication
• can understand and follow the protocol requirements and instructions

Exclusion criteria:

• smokes at least 4 packs per day in the past 12 months
• use of prescription or non-prescription drug(s)
• herbal or dietary supplements or vitamins with 14 days prior to first dose of study medication
• a clinically relevant abnormality medical condition or circumstance making the subject unsuitable for the study per the study doctor
• blood donation in excess of 1 pint within 56 days before dosing of medication
• iron deficient
• history or drug allergy of study medication
• history of drug or alcohol abuse or dependency within the past 6 months
• subjects cannot use any nicotine-containing products within the last 6 months
• positive for HIV, Hepatitis B or C
• active peptic ulcer disease
• uncontrolled nausea and vomiting
• active infection
• heart failure
• female who is lactating
• female who has a positive pregnancy test